{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee KH"],"funding":["Rural Development Administration&apos;s Regional Specialized Crop Technology Development Project"],"pagination":["30467-30488"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12290619"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(28)"],"pubmed_abstract":["Age-related macular degeneration (AMD) is a progressive, late-onset, genetic (CFH, HTRA), and environmental (smoking, aging) ocular disease that is a leading cause of blindness affecting more than 200 million people worldwide. New treatments are required for fibrosis, autophagy, and microglia-driven pathologies in AMD patients for personalized medicine approaches, considering that only 10% of AMD patients are treated using the current medicine. The current study examined ninety-one compounds using a phenotypic drug discovery platform <i>in vitro</i> and <i>in vivo</i> to find potential drug candidates that include a new chemical entity (NCE) and extracts from plants such as , , and . The phenotypic drug discovery platform determined mitochondrial function quantitatively by measuring the ox"],"journal":["ACS omega"],"pubmed_title":["Phenotypic Drug Discovery Platform by Quantitative High-Throughput Screening Identifies Antiapoptotic Molecules in a Zebrafish Model of Age-Related Macular Degeneration."],"pmcid":["PMC12290619"],"funding_grant_id":["PJ01696801"],"pubmed_authors":["Jahng WJ","Stewart JM","Jung J","Jeong EH","Choo DW","Seong HW","Ahn GH","Kim JS","Ryu JM","Park B","Yoo GS","Kim YS","Samadi AF","Jee DH","Lee KH","Jin L"],"additional_accession":[]},"is_claimable":false,"name":"Phenotypic Drug Discovery Platform by Quantitative High-Throughput Screening Identifies Antiapoptotic Molecules in a Zebrafish Model of Age-Related Macular Degeneration.","description":"Age-related macular degeneration (AMD) is a progressive, late-onset, genetic (CFH, HTRA), and environmental (smoking, aging) ocular disease that is a leading cause of blindness affecting more than 200 million people worldwide. New treatments are required for fibrosis, autophagy, and microglia-driven pathologies in AMD patients for personalized medicine approaches, considering that only 10% of AMD patients are treated using the current medicine. The current study examined ninety-one compounds using a phenotypic drug discovery platform <i>in vitro</i> and <i>in vivo</i> to find potential drug candidates that include a new chemical entity (NCE) and extracts from plants such as , , and . The phenotypic drug discovery platform determined mitochondrial function quantitatively by measuring the ox","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-05-09T17:53:58.279Z","creation":"2026-04-08T01:08:01.875Z"},"accession":"S-EPMC12290619","cross_references":{"pubmed":["40727801"],"doi":["10.1021/acsomega.5c02227"]}}